Freis E D, Papademetriou V
Drugs. 1985 Dec;30(6):469-74. doi: 10.2165/00003495-198530060-00001.
The proposal that thiazide diuretics may increase cardiovascular risk receives no support from recent data. Current evidence does not indicate that diuretic-induced hypokalaemia is associated with increased ventricular arrhythmias. This evidence includes continuous electrocardiographic monitoring--which is the most sensitive technique for quantitating cardiac arrhythmias. In contrast to earlier reports, more recent studies found no evidence for increased arrhythmias during the period of hypokalaemia, or for decreased arrhythmic activity after correction of hypokalaemia. Similarly, studies claiming increased sudden death in patients on diuretic treatment have not been substantiated by the results of other large-scale trials. Elevation of serum cholesterol concentrations with thiazide appears to be a short term phenomenon since most studies indicate the elevation reverts to baseline during long term treatment. Thiazide diuretics remain as one of our most effective antihypertensive agents. Fears of their increasing the incidence of ventricular arrhythmias due to hypokalaemia, or constituting a risk factor for atherosclerosis by elevating serum cholesterol concentrations, appear largely unsubstantiated.
噻嗪类利尿剂可能增加心血管风险这一观点未得到近期数据的支持。目前的证据并未表明利尿剂诱发的低钾血症与室性心律失常增加有关。这一证据包括连续心电图监测——这是定量心律失常最敏感的技术。与早期报告相反,最近的研究未发现低钾血症期间心律失常增加或低钾血症纠正后心律失常活动减少的证据。同样,声称利尿剂治疗患者猝死增加的研究也未得到其他大规模试验结果的证实。噻嗪类药物使血清胆固醇浓度升高似乎是一种短期现象,因为大多数研究表明,在长期治疗期间这种升高会恢复到基线水平。噻嗪类利尿剂仍然是我们最有效的抗高血压药物之一。因低钾血症而担心其增加室性心律失常的发生率,或因升高血清胆固醇浓度而构成动脉粥样硬化的危险因素,这些担忧在很大程度上似乎没有根据。